The latest trend gaining momentum in the market is the adoption of replacement gene therapy. Ovarian cancer has the lowest survival rate among all the other types of gynecological cancers.
Epithelial ovarian cancer (EOC) is the most common ovarian cancer witnessed among patients.
Players in the ovarian cancer immunotherapies market have come up with few chemotherapy products that are commercially successful. However, chemotherapy can cause blood-related complications by damaging the blood-producing cells of the bone marrow.
This in turn is fueling the popularity of gene therapy which is expected to be one of the biggest paradigm shifts in pharmacology.
Major key players in the gene therapy for ovarian cancer: Takara Bio, VBL, Therapeutics, Targovax, CELSION, Lokon Pharma, SiBiono GeneTech, and Advantagene
Ovarian cancer occurs and arises from several types of cells within the ovary, and it has the lowest survival rate of all gynecological cancers. Among many types, epithelial ovarian cancer (EOC) is the most common ovarian cancer, whereas ovarian low malignant potential tumor (OLMPT), germ cell tumor, and stromal ovarian tumor are some of the less common types.
It is the seventh most common cancer in women globally and 18th most common cancer overall. The ovarian cancer immunotherapies market has already got some commercially successful chemotherapy products.
However, chemotherapy often involves a combination of two or more drugs, given intravenously every 3-4 weeks, and mostly associated with long-lasting side/adverse effects. Various studies have shown that chemotherapy can damage the blood-producing cells of the bone marrow, resulting in blood-related complications.
Report at www.reportsnreports.com/.aspx?name=1286829.
Key questions answered in this report
What will the market size be in 2022 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
Few Points from List of Exhibits Provided in Global Gene Therapy for Ovarian Cancer- A Pipeline Analysis:
Exhibit 1: Drug Approval Process by Us Fda
Exhibit 2: Pipeline Landscape
Exhibit 3: Pipeline Molecules by Vendors
Exhibit 4: Pipeline Molecules by Numbers
Exhibit 5: Pipeline Molecules by Percentage
Exhibit 6: Overview: P53 Gene Therapy
Exhibit 7: Clinical Trials Description of P53 Gene
Exhibit 8: Overview: Ofranergene Obadenovec
Exhibit 9: Clinical Trials Description of Ofranergene Obadenovec
Exhibit 10: Overview: Gen-1
Exhibit 11: Clinical Trials Description of Gen-1
Exhibit 12: Overview: Load703
Exhibit 13: Clinical Trials Description of Load703
Exhibit 14: Overview: Oncos-102
Exhibit 15: Clinical Trials Description of Oncos-102